News
AKTX
1.753
+13.84%
0.213
Akari gains despite leadership change amid portfolio shakeup
Akari Therapeutics (NASDAQ:AKTX) shares traded higher in the morning hours on Wednesday. The company announced a portfolio prioritization plan alongside new appointments to key management positions. Samir Patel will take over as interim CEO of the U.K.-based biotech. Akari and Peak Bio announced a proposed merger.
Seeking Alpha · 7h ago
*Akari Therapeutics Sees Cost Savings Through Reduced Clinical Trial, Infrastructure Costs >AKTX
Dow Jones · 9h ago
Akari Therapeutics And Peak Bio Announce Portfolio Prioritization Plan For Combined Go-Forward Merger Entity
Benzinga · 9h ago
AKARI THERAPEUTICS PLC - EXPECTS TO ACHIEVE COST SAVINGS THROUGH REDUCED CLINICAL TRIAL AND INFRASTRUCTURE COSTS
Reuters · 10h ago
AKARI THERAPEUTICS PLC - MELISSA BRADFORD-KLUG WILL STEP DOWN AS AKARI'S CHIEF OPERATING OFFICER
Reuters · 10h ago
SAMIR R. PATEL, M.D. APPOINTED INTERIM CEO FOR AKARI THERAPEUTICS
Reuters · 10h ago
Weekly Report: what happened at AKTX last week (0422-0426)?
Weekly Report · 2d ago
Weekly Report: what happened at AKTX last week (0415-0419)?
Weekly Report · 04/22 10:02
Weekly Report: what happened at AKTX last week (0408-0412)?
Weekly Report · 04/15 09:57
Weekly Report: what happened at AKTX last week (0401-0405)?
Weekly Report · 04/08 10:00
Akari Therapeutics Non-GAAP EPS of $0.00
Seeking Alpha · 04/01 10:59
AKARI THERAPEUTICS REPORTS FULL-YEAR 2023 FINANCIAL RESULTS AND RECENT HIGHLIGHTS
Reuters · 04/01 10:30
Weekly Report: what happened at AKTX last week (0325-0329)?
Weekly Report · 04/01 09:59
Weekly Report: what happened at AKTX last week (0318-0322)?
Weekly Report · 03/25 10:01
Weekly Report: what happened at AKTX last week (0311-0315)?
Weekly Report · 03/18 09:59
Weekly Report: what happened at AKTX last week (0304-0308)?
Weekly Report · 03/11 09:58
Akari Therapeutics rises on all stock deal with Peak Bio
Seeking Alpha · 03/05 15:08
Akari Therapeutics Announces Strategic Merger with Peak Bio
TipRanks · 03/05 13:43
Akari Therapeutics Signs Merger-of-Equals with Peak Bio
Akari Therapeutics and Peak Bio have agreed to an all-stock merger of equals. The biotechnology companies will continue to operate under the Akari banner. Shareholders of each company are set to receive about 50% equity in the new company. The deal is expected to close late in the second quarter.
Dow Jones · 03/05 13:23
*Akari Therapeutics, Peak: Exchange Expected to Result in Implied Equity Ownership in Combined Co of About 50% for Akari Hldrs and About 50% for Peak Stockholders >AKTX
Dow Jones · 03/05 13:05
More
Webull provides a variety of real-time AKTX stock news. You can receive the latest news about Akari Therapeutics Plc through multiple platforms. This information may help you make smarter investment decisions.
About AKTX
Akari Therapeutics, Plc is a late-stage biotechnology company. The Company is developing advanced therapies for autoimmune and inflammatory diseases. Its lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. Its pipeline includes a Phase 3 clinical trial program investigating nomacopan for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). It is conducting a clinical trial of subcutaneous nomacopan for the treatment of HSCT-TMA in pediatrics. The United States Food and Drug Administration (FDA) has granted Rare Pediatric Disease, Orphan Drug, and Fast Track designations to nomacopan for the treatment of pediatric HSCT-TMA. It is also investigating long-acting PASylated-nomacopan (PAS-nomacopan) for treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD) in preclinical studies.